MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.71
+0.01
+0.13%
After Hours: 7.85 +0.14 +1.82% 18:02 10/19 EDT
OPEN
9.20
PREV CLOSE
7.70
HIGH
10.13
LOW
7.25
VOLUME
2.26M
TURNOVER
--
52 WEEK HIGH
19.10
52 WEEK LOW
1.580
MARKET CAP
74.08M
P/E (TTM)
-12.3558
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Edesa on go with Phase 2/3 study of EB05 in COVID-19
The FDA has signed off on a Phase 2/3 clinical trial evaluating Edesa Biotech's ([[EDSA]] -3.6%) EB05 in hospitalized COVID-19 patients who have acute respiratory distress syndrome ((ARDS)) or are
Seekingalpha · 15h ago
Edesa receives FDA approval to initiate Covid studies in the US
Edesa Biotech ([[EDSA]] +3.1%), receives FDA clearance to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for treatment of Covid-19.EB05 is an
Seekingalpha · 15h ago
Edesa Biotech Receives Approval To Initiate COVID-19 Study In US
TORONTO, ON / ACCESSWIRE / October 19, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) to begin the Phase
Benzinga · 18h ago
Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.
TORONTO, ON / ACCESSWIRE / October 19, 2020 / Edesa Biotech, Inc.
ACCESSWIRE · 18h ago
CEO Pardeep Nijhawan increases stake in Edesa Biotech
Edesa Biotech (EDSA) is up 5.56% pre-market following disclosure that CEO Pardeep Nijhawan increases its stake to 34.4% in the company.The increase accounts for 3.96% in a series of transaction, including private
Seekingalpha · 09/18 13:02
LD Micro -- 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
ACCESSWIRE · 08/31 22:00
EDSA: Set to Initiate Clinical Trial of EB05 in COVID-19 Patients
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Clinical Trial of EB05 Set to Initiate In April 2020, Edesa (NASDAQ:EDSA) announced an exclusive licensing agreement with Light Chain Bioscience for two clinical-stage monoclonal antibody assets targeting toll-like receptor
Zacks Small Cap Research · 08/21 21:02
Edesa Biotech Q3 EPS $(0.20) Up From $(0.30) YoY, Sales $110K
Benzinga · 08/12 11:49
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDSA. Analyze the recent business situations of Edesa Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EDSA stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 15
Institutional Holdings: 175.83K
% Owned: 1.83%
Shares Outstanding: 9.61M
TypeInstitutionsShares
Increased
0
0
New
1
120.41K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Independent Director
Sean MacDonald
President
Michael Brooks
Chief Executive Officer/Director
Pardeep Nijhawan
Chief Financial Officer/Secretary
Kathi Niffenegger
Director
Frank Oakes
Independent Director
Lorin Johnson
Independent Director
Paul Pay
Independent Director
Carlo Sistilli
Independent Director
Peter van der Velden
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EDSA
Edesa Biotech Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical-stage drugs for dermatological and gastrointestinal indications. Its lead product candidate, EB01, is an sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD). Its pipeline also includes EB02 and EB04. EB02, an sPLA2 inhibitor, is being developed as a treatment for patients with hemorrhoids disease (HD). EB04 is being developed for anal fissures. It is also focused on developing biologic drug candidates for therapeutic, prophylactic and diagnostic applications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Edesa Biotech Inc stock information, including NASDAQ:EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.